Daniel Johnson, PhD
Professor
Otolaryngology
School of Medicine

Dr. Johnson earned his MA and PhD in molecular biology from Princeton University, followed by a postdoctoral fellowship at the University of California, San Francisco. Prior to joining UCSF OHNS Department in 2016, Dr. Johnson was a Professor in the Division of Hematology/Oncology, Department of Medicine, and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Pennsylvania. Dr. Johnson was also the Scientific Director of the Acute Leukemia Working group at the University of Pittsburgh Cancer Institute.

Dr. Johnson has over 120 publications and is Editor of two books, entitled “Cell Death Signaling in Cancer Biology and Treatment” and “Targeting Cell Survival Pathways to Enhance Response to Chemotherapy”. He has maintained continuous NIH funding as a principal investigator since 1995, and has served as a standing member for both NIH and ACS study sections. Dr. Johnson continues to play an active role on multiple review panels for the NIH, VA, and other granting agencies, and serves on the Board of Scientific Counselors for NIH NIDCD. Since 2001 he has served as a Section Editor for Leukemia, the top-ranked journal for hematologic malignancies, and has also served as Editor for Cancer Research and Oncology Research. Dr. Johnson places a high priority on translating findings from his lab to the clinic, and has facilitated the development of clinical trials in both leukemia and head and neck cancer.

Dr. Johnson greatly values teaching and serving as a mentor for individuals with a broad variety of educational backgrounds. He has served as primary mentor or co-mentor for 68 trainees. Most of his trainees have gone on to higher academic or clinical positions, including several who are now faculty members at academic institutions. He was the first lab-based faculty to be awarded the G. David Roodman Excellence in Mentorship Award by the University of Pittsburgh Hematology/Oncology Clinical Fellows. At the University of Pittsburgh he also was a leader for the Career Mentoring Program for junior faculty, and taught extensively in both the graduate and medical schools. He is a faculty member of the BMS Graduate Program at UCSF.

Research: Dr. Johnson’s research is focused on understanding the molecular mechanisms that contribute to the origin and progression of head and neck squamous cell carcinoma (HNSCC), and the development of novel therapeutic agents and strategies for this disease. He is particularly interested in combating the intrinsic and acquired resistance to anti-cancer agents that characterizes the majority of HNSCC patient tumors. Work from his lab has shown that overexpression of anti-apoptotic Bcl-2 family members and/or hyperactivation of STAT3 transcription factor contribute to HNSCC drug resistance. He has employed small molecule inhibitors of Bcl-2/Bcl-XL/Mcl-1, as well as proteasome inhibitors, to develop synergistic co-targeting strategies to overcome resistance arising for overexpression of Bcl-2 family members. To combat the effects of STAT3 hyperactivation, he has co-invented an highly novel decoy oligonucleotide inhibitor for this previously undruggable oncogene. Current efforts are focused on moving the STAT3 decoy to clinical evaluation in patients with HNSCC. Additional studies in his lab have shown that mutations in caspase-8 protease, which occur frequently in HNSCC tumors, contribute to disease progression by abrogating cell death mediated by death ligands such as TRAIL and TNF. Ongoing studies are aimed at developing further in vivo and organoid models of HNSCC for investigation of drug resistance mechanisms and evaluation of novel precision medicine therapeutic strategies.

Specialty: Head and Neck Oncology

Expertise: Molecular biology and molecular genetics of head and neck cancer, anti-cancer drug development

Professional Interests: Development of new therapeutic strategies and agents for head and neck cancer, mechanisms of chemotherapy resistance, cell death mechanisms, mentoring

Education and Training:

• Graduate School: Princeton University, NJ – M.A., Molecular Biology
• Graduate School: Princeton University, NJ – Ph.D., Molecular Biology
• Postdoctoral Fellowship: University of California, San Francisco Awards and Honors:

• 2019-present - NIDCD Board of Scientific Counselors
• 2015-present – Oncology Research Editorial Board
• 2014 – G. David Roodman Excellence in Mentorship Award from Hematology/Oncology Fellows
• 2010-2013 – Cancer Research Editorial Board
• 2007 – Hillman Fellow for Innovative Cancer Research
• 2001-present – Leukemia Section Editor
• 1999-present – Leukemia Editorial Board
• 1994-95 – Fellow of the Lymphoma Research Foundation of America
• 1990 – Henry Christian Outstanding Abstract in Cardiology, AFCR
• 1988-1992 – Fellow of the Cardiovascular Research Institute, UCSF
• 1989 – American Heart Association Postdoctoral Fellowship
• 1982 – Graduated summa cum laude, North Park College
• 1981 – Walter E. Olson Memorial Scholarship Fund
• 1981 – J. Paul Bennett Chemistry Award
• 1980-82 – President, North Park University Mathematics Society
• 1979 – Oscar E. Olson Memorial Scholarship Fund in Mathematics

• Author Correction: Head and neck squamous cell carcinoma.
  Nature reviews. Disease primers 2023 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
• Transcription Factors and Cancer: Approaches to Targeting.
  Cancer journal (Sudbury, Mass.) 2023 Shiah JV, Johnson DE, Grandis JR
• The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.
  Advances in biological regulation 2022 VanLandingham NK, Nazarenko A, Grandis JR, Johnson DE
• STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Qureshy Z, Li H, Zeng Y, Rivera J, Cheng N, Peterson CN, Kim MO, Ryan WR, Ha PK, Bauman JE, Wang SJ, Long SR, Johnson DE, Grandis JR
• Emerging tyrosine kinase inhibitors for head and neck cancer.
  Expert opinion on emerging drugs 2022 Long Z, Grandis JR, Johnson DE
• NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.
  Cancers 2022 Li H, Peyser ND, Zeng Y, Ha PK, Johnson DE, Grandis JR
• Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
  The Journal of clinical investigation 2021 Jin N, Keam B, Cho J, Lee MJ, Kim HR, Torosyan H, Jura N, Ng PK, Mills GB, Li H, Zeng Y, Barbash Z, Tarcic G, Kang H, Bauman JE, Kim MO, VanLandingham NK, Swaney DL, Krogan NJ, Johnson DE, Grandis JR
• Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.
  JCI insight 2021 Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, Mills GB, Vandenberg S, Swaney DL, Johnson DE, …
• Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009-2018.
  Cancers 2021 Warren BR, Grandis JR, Johnson DE, Villa A
• A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.
  Science (New York, N.Y.) 2021 Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Zeng Y, McGregor M, Herrington KA, O'Keefe R, Jin N, VanLandingham NK, Foussard H, Von Dollen J, Bouhaddou M, Jimenez…
• Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR
• Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction.
  Cell death & disease 2021 Cui Z, Dabas H, Leonard BC, Shiah JV, Grandis JR, Johnson DE
• PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
  Head & neck 2021 Bhola NE, Njatcha C, Hu L, Lee ED, Shiah JV, Kim MO, Johnson DE, Grandis JR
• Head and neck squamous cell carcinoma.
  Nature reviews. Disease primers 2020 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
• Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.
  Molecular cancer therapeutics 2020 Shiah JV, Grandis JR, Johnson DE
• Head and neck squamous cell carcinoma. Nature Reviews Disease Primers. In Press
  Head and neck squamous cell carcinoma. Nature Reviews Disease Primers. In Press. 2020 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR
• CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.
  Molecular cancer research : MCR 2020 Cui Z, Kang H, Grandis JR, Johnson DE
• Targeting the JAK/STAT pathway in solid tumors.
  Journal of cancer metastasis and treatment 2020 Qureshy Z, Johnson DE, Grandis JR
• Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
  Molecular cancer therapeutics 2020 Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS
• Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.
  Biochimica et biophysica acta. Molecular cell research 2020 Lee MJ, Jin N, Grandis JR, Johnson DE
• Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
  PloS one 2020 O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR
• Targeting STAT3 in Cancer with Nucleotide Therapeutics.
  Cancers 2019 Lau YK, Ramaiyer M, Johnson DE, Grandis JR
• Gene targets of sulforaphane in head and neck squamous cell carcinoma.
  Molecular medicine reports 2019 Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE
• NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer.
  Advances in biological regulation 2019 Cai Y, Yousef A, Grandis JR, Johnson DE
• ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin.
  Oral oncology 2019 Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE
• Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
  Expert opinion on investigational drugs 2019 Sola AM, Johnson DE, Grandis JR
• Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
  The Journal of experimental medicine 2019 Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, …
• Modulation of the PI3K/mTOR pathways. In: Improving the therapeutic ratio in head and neck cancer. Editor: Randy Kimple. Elsevier. Pgs. 89-105. ISBN: 978-0-12-817868-3
  Modulation of the PI3K/mTOR pathways. In: Improving the therapeutic ratio in head and neck cancer. Editor: Randy Kimple. Elsevier. Pgs. 89-105. ISBN: 978-0-12-817868-3. 2019 Galstyan A, Cho J, Johnson DE, Grandis JR
• An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
  Expert opinion on emerging drugs 2018 Lee YS, Johnson DE, Grandis JR
• STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
  Molecular cancer therapeutics 2018 Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM
• Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.
  International journal of molecular sciences 2018 Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE
• New Therapies in Head and Neck Cancer.
  Trends in cancer 2018 Santuray RT, Johnson DE, Grandis JR
• A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
  Leukemia & lymphoma 2018 Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE
• Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
  Cancer research 2018 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR
• Leveraging Genomics for Head and Neck Cancer Treatment.
  Journal of dental research 2018 Kemmer JD, Johnson DE, Grandis JR
• Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
  Nature reviews. Clinical oncology 2018 Johnson DE, O'Keefe RA, Grandis JR
• Jak/STAT signaling in head and neck cancer. In: Molecular Determinants of Head and Neck Cancer. Editors: Burtness B and Golemis E. Springer. Pgs. 155-184. ISBN: 978-3-319-78762-6
  Jak/STAT signaling in head and neck cancer. In: Molecular Determinants of Head and Neck Cancer. Editors: Burtness B and Golemis E. Springer. Pgs. 155-184. ISBN: 978-3-319-78762-6. 2018 Cedars E, Johnson DE, Grandis JR
• PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 6, pgs. 123-144. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,
  PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 6, pgs. 123-144. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7, 2018 Zhu RT, Gutkind JS, Johnson DE, Grandis JR
• STAT3 as a major contributor to chemoresistance. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 7, pgs. 145-167. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,
  STAT3 as a major contributor to chemoresistance. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 7, pgs. 145-167. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7, 2018 Lee DS, Grandis JR, Johnson DE
• Targeting members of the epidermal growth factor receptor family to improve response to chemotherapy. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 1, pgs. 1-23. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,
  Targeting members of the epidermal growth factor receptor family to improve response to chemotherapy. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 1, pgs. 1-23. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7, 2018 O’Keefe RA, Grandis JR, Johnson DE
• The JNK pathway in drug resistance. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 4, pgs. 87-100. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,
  The JNK pathway in drug resistance. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 4, pgs. 87-100. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7, 2018 Hu L, Zou F, Grandis JR, Johnson DE
• Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.
  Seminars in radiation oncology 2018 Cho J, Johnson DE, Grandis JR
• Signaling by cell surface death receptors: Alterations in head and neck cancer.
  Advances in biological regulation 2017 Leonard BC, Johnson DE
• EGFR-targeted therapies in the post-genomic era.
  Cancer metastasis reviews 2017 Xu MJ, Johnson DE, Grandis JR
• When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.
  Cancer prevention research (Philadelphia, Pa.) 2017 Johnson DE, Bauman JE
• Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR
• Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.
  PloS one 2016 Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR
• A sensible approach to targeting STAT3-mediated transcription.
  Annals of translational medicine 2016 Bhola NE, Johnson DE, Grandis JR
• Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane.
  Cancer prevention research (Philadelphia, Pa.) 2016 Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE
• STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
  Cancer prevention research (Philadelphia, Pa.) 2016 Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR
• Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
  Oncogene 2015 Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR
• Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions.
  Oral oncology 2015 Sheth SH, Johnson DE, Kensler TW, Bauman JE
• An ATRActive future for differentiation therapy in AML.
  Blood reviews 2015 Johnson DE, Redner RL
• Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: challenges and new Approaches. In: Resistance to Proteasome Inhibitors in Cancer. Editor: Q. Ping Dou. Springer. ISBN: 978-3-319-06752-0
  Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: challenges and new Approaches. In: Resistance to Proteasome Inhibitors in Cancer. Editor: Q. Ping Dou. Springer. ISBN: 978-3-319-06752-0. 2015 Kass JI, Grandis JR, and Johnson DE
• You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
  Leukemia 2014 Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT
• Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
  Cancer biology & therapy 2014 Zang Y, Kirk CJ, Johnson DE
• STAT transcription factors in normal and cancer stem cells.
  Advances in biological regulation 2014 Dorritie KA, Redner RL, Johnson DE
• Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth.
  Molecular oncology 2014 Li C, Egloff AM, Sen M, Grandis JR, Johnson DE
• DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
  Leukemia 2014 Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M
• The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
  Endocrine-related cancer 2014 Johnson DE
• Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.
  Molecular medicine (Cambridge, Mass.) 2014 Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR
• Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, …
• Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.
  Oral oncology 2013 Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE
• STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.
  Leukemia 2013 Dorritie KA, McCubrey JA, Johnson DE
• Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
  Cell cycle (Georgetown, Tex.) 2013 Li C, Johnson DE
• The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
  Autophagy 2012 Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE
• Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE
• Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR
• First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.
  Cancer discovery 2012 Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, …
• Guidelines for the use and interpretation of assays for monitoring autophagy.
  Autophagy 2012 Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes …
• Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit.
  Chinese journal of cancer 2012 Johnson DE
• Defective apoptosis signaling in cancer. In: Cell Death Signaling in Cancer Biology and Treatment. Chapter 1, pgs. 1-34. Editor: DE Johnson. Springer. ISBN: 978-1-4614-5846-3,
  Defective apoptosis signaling in cancer. In: Cell Death Signaling in Cancer Biology and Treatment. Chapter 1, pgs. 1-34. Editor: DE Johnson. Springer. ISBN: 978-1-4614-5846-3, 2012 Johnson DE
• Leading small molecule inhibitors of anti-apoptotic Bcl-2 family members. In: Cell Death Signaling in Cancer Biology and Treatment. Chapter 9, pgs. 231-253. Editor: DE Johnson. Springer. ISBN: 978-1-4614-5846-3,
  Leading small molecule inhibitors of anti-apoptotic Bcl-2 family members. In: Cell Death Signaling in Cancer Biology and Treatment. Chapter 9, pgs. 231-253. Editor: DE Johnson. Springer. ISBN: 978-1-4614-5846-3, 2012 Yazbeck VY and Johnson DE
• Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
  Cancer letters 2011 Li C, Johnson DE
• Dasatinib promotes ATRA-induced differentiation of AML cells.
  Leukemia 2009 Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE
• Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
  Carcinogenesis 2009 Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR
• CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients.
  Cell cycle (Georgetown, Tex.) 2009 Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L, Ge Y, Johnson DE, Ju S, Shu Y
• Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
  Molecular cancer therapeutics 2009 Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE
• Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target.
  Leukemia 2009 Jones JE, Wang L, Kropf PL, Duan R, Johnson DE
• ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
  Molecular pharmacology 2009 Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE
• Lack of toxicity of a STAT3 decoy oligonucleotide.
  Cancer chemotherapy and pharmacology 2008 Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR
• Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
  Molecular cancer therapeutics 2008 Li C, Li R, Grandis JR, Johnson DE
• Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
  Molecular pharmacology 2008 Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR
• Gefitinib potentiates myeloid cell differentiation by ATRA.
  Leukemia 2008 Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE
• Inhibitors of the Bcl-2 protein family as sensitizers to anticancer agents. In: Sensitization of Cancer Cells to Chemo/Immuno/Radio Therapy. Editors: B Bonavida and B Teicher. Humana Press, Inc., pgs. 243-261. ISBN: 978-1-59745-474-2
  Inhibitors of the Bcl-2 protein family as sensitizers to anticancer agents. In: Sensitization of Cancer Cells to Chemo/Immuno/Radio Therapy. Editors: B Bonavida and B Teicher. Humana Press, Inc., pgs. 243-261. ISBN: 978-1-59745-474-2. 2008 Johnson DE
• Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation.
  Molecular cancer therapeutics 2007 Miranda MB, Redner RL, Johnson DE
• Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.
  Advances in enzyme regulation 2007 Johnson DE
• Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.
  Neoplasia (New York, N.Y.) 2007 Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE
• Signal transduction pathways that contribute to myeloid differentiation.
  Leukemia 2007 Miranda MB, Johnson DE
• Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.
  Molecular pharmacology 2007 Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR
• Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells.
  Cancer research 2006 Herman-Antosiewicz A, Johnson DE, Singh SV
• Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway.
  Leukemia research 2005 Miranda MB, Xu H, Torchia JA, Johnson DE
• Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death.
  Molecular cancer therapeutics 2005 Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE
• (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.
  Molecular cancer therapeutics 2005 Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE
• Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides.
  Molecular cancer therapeutics 2004 Shangary S, Oliver CL, Tillman TS, Cascio M, Johnson DE
• Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2.
  Oncogene 2004 Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ, Singh SV
• The intrinsic (mitochondrial) death pathway and new cancer therapeutics: Bcl-2 family in focus. In: Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Editors: M Los and SB Gibson. Kluwer Academic Press. ISBN: 0-387-23384-9,
  The intrinsic (mitochondrial) death pathway and new cancer therapeutics: Bcl-2 family in focus. In: Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Editors: M Los and SB Gibson. Kluwer Academic Press. ISBN: 0-387-23384-9, 2004 Shangary S, Oliver CL, Johnson DE
• Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Lango M, Wentzel AL, Song JI, Xi S, Johnson DE, Lamph WW, Miller L, Grandis JR
• Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.
  Leukemia 2003 Shangary S, Johnson DE
• Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR
• Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells.
  Leukemia 2003 Miranda MB, Dyer KF, Grandis JR, Johnson DE
• Potentiation of tumor necrosis factor-alpha-induced cell death by rottlerin through a cytochrome-C-independent pathway.
  Experimental cell research 2002 Basu A, Johnson DE, Woolard MD
• Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death.
  Biochemistry 2002 Shangary S, Johnson DE
• Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
  Leukemia 2002 Miranda MB, McGuire TF, Johnson DE
• Isolation of Bcl-2 binding proteins that exhibit homology with BAG-1 and suppressor of death domains protein.
  Biochemical and biophysical research communications 2001 Antoku K, Maser RS, Scully WJ, Delach SM, Johnson DE
• A distinct pathway of cell-mediated apoptosis initiated by granulysin.
  Journal of immunology (Baltimore, Md. : 1950) 2001 Kaspar AA, Okada S, Kumar J, Poulain FR, Drouvalakis KA, Kelekar A, Hanson DA, Kluck RM, Hitoshi Y, Johnson DE, Froelich CJ, Thompson CB, Newmeyer DD, Anel A, Clayberger C, Krensky AM
• Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis.
  Oncogene 2001 Fattman CL, Delach SM, Dou QP, Johnson DE
• Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade.
  Cancer research 2000 Gastman BR, Yin XM, Johnson DE, Wieckowski E, Wang GQ, Watkins SC, Rabinowich H
• Analysis of the role of conserved cysteine residues in the bcl-2 oncoprotein.
  Biochemical and biophysical research communications 2000 Maser RS, Antoku K, Scully WJ, Cho RL, Johnson DE
• Noncaspase proteases in apoptosis.
  Leukemia 2000 Johnson DE
• p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis.
  Molecular medicine (Cambridge, Mass.) 2000 Steinman RA, Johnson DE
• Programmed cell death regulation: basic mechanisms and therapeutic opportunities.
  Leukemia 2000 Johnson DE
• Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells.
  Experimental cell research 2000 Gamen S, Anel A, Pérez-Galán P, Lasierra P, Johnson D, Piñeiro A, Naval J
• Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.
  Proceedings of the National Academy of Sciences of the United States of America 2000 Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD
• Inhibitor of apoptosis protein hILP undergoes caspase-mediated cleavage during T lymphocyte apoptosis.
  Cancer research 2000 Johnson DE, Gastman BR, Wieckowski E, Wang GQ, Amoscato A, Delach SM, Rabinowich H
• Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events.
  Blood 2000 Gastman BR, Johnson DE, Whiteside TL, Rabinowich H
• Caspase-mediated degradation of T-cell receptor zeta-chain.
  Cancer research 1999 Gastman BR, Johnson DE, Whiteside TL, Rabinowich H
• Characterization of caspase proteases in cytokine-dependent myeloid progenitor cells using enzyme affinity labeling.
  Journal of cellular biochemistry 1999 Cho RL, Johnson DE
• Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium.
  Clinical cancer research : an official journal of the American Association for Cancer Research 1998 Drenning SD, Marcovitch AJ, Johnson DE, Melhem MF, Tweardy DJ, Grandis JR
• IL-3 withdrawal activates a CrmA-insensitive poly(ADP-ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells.
  Leukemia 1998 Antoku K, Liu Z, Johnson DE
• Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawal.
  Frontiers in bioscience : a journal and virtual library 1998 Johnson DE
• Bcl-2- and CrmA-inhibitable dephosphorylation and cleavage of retinoblastoma protein during etoposide-induced apoptosis.
  International journal of molecular medicine 1998 An B, Johnson DE, Jin JR, Antoku K, Dou QP
• Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents.
  Leukemia 1997 Antoku K, Liu Z, Johnson DE
• Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family.
  Journal of cellular biochemistry 1997 Dou QP, An B, Antoku K, Johnson DE
• Bcl-2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat-induced apoptosis.
  The American journal of physiology 1997 Fabisiak JP, Kagan VE, Ritov VB, Johnson DE, Lazo JS
• A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression.
  The Journal of biological chemistry 1995 Morishita K, Johnson DE, Williams LT
• Signalling by receptor tyrosine kinases.
  Annual review of biochemistry 1993 Fantl WJ, Johnson DE, Williams LT
• Structural and functional diversity in the FGF receptor multigene family.
  Advances in cancer research 1993 Johnson DE, Williams LT
• Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities.
  Molecular and cellular biology 1992 Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT
• The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain.
  Molecular and cellular biology 1991 Johnson DE, Lu J, Chen H, Werner S, Williams LT
• Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3.
  Proceedings of the National Academy of Sciences of the United States of America 1991 Keegan K, Johnson DE, Williams LT, Hayman MJ
• Characterization of the FGFR-3 gene and its gene product.
  Annals of the New York Academy of Sciences 1991 Keegan K, Johnson DE, Williams LT, Hayman MJ
• Diverse forms of a receptor for acidic and basic fibroblast growth factors.
  Molecular and cellular biology 1990 Johnson DE, Lee PL, Lu J, Williams LT
• Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor.
  Science (New York, N.Y.) 1989 Lee PL, Johnson DE, Cousens LS, Fried VA, Williams LT
• DNA polymorphisms for the nerve growth factor receptor gene exclude its role in familial dysautonomia.
  Molecular biology & medicine 1986 Breakefield XO, Ozelius L, Bothwell MA, Chao MV, Axelrod F, Kramer PL, Kidd KK, Lanahan AA, Johnson DE, Ross AH
• Expression and structure of the human NGF receptor.
  Cell 1986 Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M
• The epidermal growth factor (EGF) receptor gene studied using gene transfer.
  The International journal of neuroscience 1985 Strazdis J, Lanahan A, Johnson DE, Bothwell M, Kucherlapati R